These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 17138058

  • 21. Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant.
    Shooshtarizadeh T, Mohammadali A, Ossareh S, Ataipour Y.
    Exp Clin Transplant; 2013 Jun; 11(3):229-33. PubMed ID: 23477385
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 24. Serial soluble CD30 measurements as a predictor of kidney graft outcome.
    Halim MA, Al-Otaibi T, Al-Muzairai I, Mansour M, Tawab KA, Awadain WH, Balaha MA, Said T, Nair P, Nampoory MR.
    Transplant Proc; 2010 Apr; 42(3):801-3. PubMed ID: 20430176
    [Abstract] [Full Text] [Related]

  • 25. CD30, a marker to detect the high-risk kidney transplant recipients.
    Spiridon C, Nikaein A, Lerman M, Hunt J, Dickerman R, Mack M.
    Clin Transplant; 2008 Apr; 22(6):765-9. PubMed ID: 19040559
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
    Grenzi PC, Campos ÉF, Tedesco-Silva H, Felipe CR, Franco MF, Soares MF, Medina-Pestana JO, Gerbase-Delima M.
    Transpl Immunol; 2013 Dec; 29(1-4):34-8. PubMed ID: 23928467
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss.
    Rodríguez LM, París SC, Arbeláez M, Cotes JM, Süsal C, Torres Y, García LF.
    Hum Immunol; 2007 Aug; 68(8):652-60. PubMed ID: 17678719
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Early post-transplant immune monitoring can predict long-term kidney graft survival: soluble CD30 levels, anti-HLA antibodies and IgA-anti-Fab autoantibodies.
    Amirzargar MA, Amirzargar A, Basiri A, Hajilooi M, Roshanaei G, Rajabi G, Mohammadiazar S, Solgi G.
    Hum Immunol; 2014 Jan; 75(1):47-58. PubMed ID: 24055694
    [Abstract] [Full Text] [Related]

  • 38. Pre-transplant level of soluble CD30 is associated with infection after heart transplantation.
    Nikaein A, Spiridon C, Hunt J, Rosenthal J, Anderson A, Eichhorn E, Magee M, Dewey T, Mack M.
    Clin Transplant; 2007 Jan; 21(6):744-7. PubMed ID: 17988268
    [Abstract] [Full Text] [Related]

  • 39. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis.
    Ye F, Ying-Bin X, Yu-Guo W, Hetzer R.
    J Heart Lung Transplant; 2009 Jan; 28(1):58-66. PubMed ID: 19134532
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.